News
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
Tharimmune, Inc. receives positive feedback from EMA on Phase 2 trial plans for TH104, a clinical candidate for pruritus in PBC, a rare liver disease -
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
Tharimmune presents positive Phase 1 data for TH104 in treating pruritus in chronic liver disease patients at ACG 2024. No opioid withdrawal effects observed, supporting safety profile -
-
-
-
-